RxDoctor Payments Data

John Roberts, MD

Ophthalmology · Colorado Springs, CONPI 1023270733

Payments from drug & device makers

$4,334in general payments, 2019–2025

Across 166 payments — averaging $26.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$712
  • Novartis$297
  • Glaukos Corporation$260
  • Aerie Pharmaceuticals, Inc.$168
  • Eyepoint US, Inc.$158
  • plus $690 from 18 others

What the payments were for

  • Food & beverage$4,334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,334 in reported general payments places this provider in the 75th percentile of 262 ophthalmology providers in Colorado.

See all ophthalmology providers in Colorado

Medicare billing

Part B allowed, 2024
$721,607
Medicare patients
939
Services billed
4,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine52$53,061
XiidraLifitegrast33$36,593
Prednisolone Acetate338$16,841
LumiganBimatoprost24$11,865
Cyclosporine18$8,968
Ketorolac Tromethamine343$8,967
MoxifloxacinMoxifloxacin Hcl303$8,500
CombiganBrimonidine Tartrate/Timolol21$7,540
RhopressaNetarsudil Mesylate11$5,110
Latanoprost291$2,881
Timolol Maleate78$1,750
Fluorometholone17$1,621
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat68$1,250
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha46$653
ValacyclovirValacyclovir Hcl23$415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$712$72,46697 claims
Bausch & Lomb Americas Inc.Xiidra$34$36,59333 claims
Aerie Pharmaceuticals, Inc.Rhopressa$168$5,11011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 262 ophthalmology providers in Colorado.

Other ophthalmology in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →